The Infectious Diseases Society of America (IDSA) asked the US government to “use every authority it has” to ensure adequate supplies of Gilead Sciences’ COVID-19 therapy remdesivir, as reported in the Financial Post.
In a letter to US Vice President Mike Pence and US Health and Human Services (HHS) Secretary Alex Azar, the group expressed concern that developed countries are relying on a single manufacturer to produce the antiviral.
“We urge the administration to fully leverage all authorities including the Defense Production Act and other tools to ensure adequate supplies of remdesivir,” the IDSA said.
Shortages of remdesivir, which the IDSA said has been critical for reducing the strain on hospitals, have been reported in several hard-hit states, prompting the HHS to ship emergency supplies to Florida, Texas, California and Arizona.
“We are concerned that the current supply of remdesivir is insufficient, particularly given dramatically escalating caseloads in many states and the likelihood of a continuing surge into the fall and winter,” the letter said.
To read more NewsPoints articles, click here.